Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,200.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,200.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,200.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $3,200.0012/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673847431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

193 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $532.33 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826451545
Principal investigator 1 Merck Sharp & Dohme Corporation $61,884.08 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848739551
Principal investigator 1 Merck Sharp & Dohme Corporation $36,219.72 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741457
Principal investigator 1 Merck Sharp & Dohme Corporation $468.33 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741459
Principal investigator 1 Merck Sharp & Dohme Corporation $16.80 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 848761933
Principal investigator 1 Merck Sharp & Dohme Corporation $12,096.04 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 848762731
Principal investigator 1 Merck Sharp & Dohme Corporation $1,265.06 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine, administered in Preadolescents and Adolescents 9 to 14 year olds with a Comparison to Young Women 16 to 26 year olds No dispute reported 06/30/2026 848763209
Principal investigator 1 Merck Sharp & Dohme Corporation $198.33 12/31/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants No dispute reported 06/30/2026 848763791
Principal investigator 1 PFIZER INC. $5,909.38 12/29/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832546498
Principal investigator 1 PFIZER INC. $18,058.74 12/29/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549907
Principal investigator 1 PFIZER INC. $20,428.48 12/28/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543361
Principal investigator 1 PFIZER INC. $41,277.43 12/24/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548825
Principal investigator 1 PFIZER INC. $1,006.25 12/23/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832543333
Principal investigator 1 PFIZER INC. $13,010.70 12/22/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832545911
Principal investigator 1 PFIZER INC. $14,274.60 12/22/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832547017
Principal investigator 1 SANOFI PASTEUR INC. $1,710.00 12/17/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366529
Principal investigator 1 PFIZER INC. $1,604.98 12/14/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832518081
Principal investigator 1 PFIZER INC. $2,834.40 12/14/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832518975
Principal investigator 1 Merck Sharp & Dohme Corporation $5,339.20 12/08/2021 Non-covered Recipient Entity
Senders Pediatrics
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848739549
Principal investigator 1 PFIZER INC. $25,735.50 12/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832549335
Principal investigator 1 PFIZER INC. $12,327.88 12/07/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832537595
Principal investigator 1 PFIZER INC. $1,045.26 12/07/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832549103
Principal investigator 1 PFIZER INC. $4,365.98 12/04/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832539165
Principal investigator 1 PFIZER INC. $29,056.38 12/02/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832543467
Principal investigator 1 PFIZER INC. $178,008.02 12/01/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832542725
Principal investigator 1 Merck Sharp & Dohme Corporation $18,072.00 11/26/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741455
Principal investigator 1 PFIZER INC. $33,504.68 11/25/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832543239
Principal investigator 1 PFIZER INC. $1,350.14 11/24/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544081
Principal investigator 1 PFIZER INC. $32,178.76 11/23/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832539983
Principal investigator 1 PFIZER INC. $1,256.25 11/23/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832542119
Principal investigator 1 PFIZER INC. $15,621.40 11/23/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546469
Principal investigator 1 PFIZER INC. $802.49 11/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832522711
Principal investigator 1 PFIZER INC. $1,417.20 11/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832524355
Principal investigator 1 PFIZER INC. $7,343.08 11/18/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543407
Principal investigator 1 PFIZER INC. $5,759.74 11/18/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832548389
Principal investigator 1 SANOFI PASTEUR INC. $8,282.00 11/17/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366515
Principal investigator 1 SANOFI PASTEUR INC. $3,720.00 11/17/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366523
Principal investigator 1 PFIZER INC. $3,375.35 11/10/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548335
Principal investigator 1 PFIZER INC. $121,922.56 11/10/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832549249
Principal investigator 1 PFIZER INC. $975.00 11/05/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832547283
Principal investigator 1 PFIZER INC. $1,949.34 11/04/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547191
Principal investigator 1 PFIZER INC. $3,020.02 10/30/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543761
Principal investigator 1 PFIZER INC. $384.51 10/29/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832536825
Principal investigator 1 PFIZER INC. $2,700.28 10/27/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543399
Principal investigator 1 SANOFI PASTEUR INC. $4,391.00 10/27/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366507
Principal investigator 1 PFIZER INC. $1,417.20 10/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832522701
Principal investigator 1 PFIZER INC. $802.49 10/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832524345
Principal investigator 1 PFIZER INC. $2,903.04 10/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832543939
Principal investigator 1 PFIZER INC. $2,344.95 10/16/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547729
Principal investigator 1 PFIZER INC. $2,143.75 10/09/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832540699
Principal investigator 1 PFIZER INC. $6,332.38 10/09/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549045
Principal investigator 1 PFIZER INC. $8,025.30 10/07/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544461
Principal investigator 1 PFIZER INC. $4,263.39 10/05/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832546081
Principal investigator 1 PFIZER INC. $17,240.32 09/28/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832548109
Principal investigator 1 PFIZER INC. $4,891.36 09/25/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547541
Principal investigator 1 PFIZER INC. $693.75 09/22/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832549129
Principal investigator 1 PFIZER INC. $7,074.25 09/21/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832545701
Principal investigator 1 PFIZER INC. $12,512.88 09/21/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548221
Principal investigator 1 PFIZER INC. $157,501.44 09/21/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832549577
Principal investigator 1 PFIZER INC. $17,733.03 09/15/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832548961
Principal investigator 1 PFIZER INC. $3,004.13 09/14/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544903
Principal investigator 1 PFIZER INC. $6,181.83 09/08/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832542863
Principal investigator 1 PFIZER INC. $76,521.60 09/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832543807
Principal investigator 1 PFIZER INC. $2,293.75 09/04/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832548549
Principal investigator 1 PFIZER INC. $14,393.98 09/03/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832545107
Principal investigator 1 PFIZER INC. $6,972.87 08/31/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544289
Principal investigator 1 PFIZER INC. $11,598.10 08/27/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832544707
Principal investigator 1 PFIZER INC. $47,341.44 08/25/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832546885
Principal investigator 1 PFIZER INC. $6,174.70 08/24/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548343
Principal investigator 1 PFIZER INC. $93,104.80 08/21/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832544557
Principal investigator 1 PFIZER INC. $9,625.10 08/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544335
Principal investigator 1 SANOFI PASTEUR INC. $8,811.00 08/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366499
Principal investigator 1 PFIZER INC. $5,539.82 08/14/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543893
Principal investigator 1 PFIZER INC. $5,368.32 08/11/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832547257
Principal investigator 1 PFIZER INC. $14,419.40 08/07/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543911
Principal investigator 1 PFIZER INC. $2,943.75 08/06/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832545712
Principal investigator 1 PFIZER INC. $13,630.12 08/05/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544913
Principal investigator 1 PFIZER INC. $7,641.82 08/03/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832545043
Principal investigator 1 PFIZER INC. $21.64 08/02/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542903
Principal investigator 1 PFIZER INC. $44,052.48 07/31/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832537589
Principal investigator 1 PFIZER INC. $47,591.68 07/24/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832547055
Principal investigator 1 PFIZER INC. $19,836.57 07/24/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547379
Principal investigator 1 PFIZER INC. $562.50 07/21/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832543248
Principal investigator 1 PFIZER INC. $9,500.00 07/21/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832545179
Principal investigator 1 PFIZER INC. $29,650.58 07/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832543883
Principal investigator 1 SANOFI PASTEUR INC. $2,197.00 07/19/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366493
Principal investigator 1 PFIZER INC. $33,622.40 07/17/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832546941
Principal investigator 1 PFIZER INC. $27,478.33 07/17/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548011
Principal investigator 1 PFIZER INC. $75.74 07/14/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544577
Principal investigator 1 PFIZER INC. $26,544.00 07/14/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832545846
Principal investigator 1 PFIZER INC. $12,864.99 07/13/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544213
Principal investigator 1 PFIZER INC. $1,731.25 07/09/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832549635
Principal investigator 1 PFIZER INC. $6,585.20 07/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546705
Principal investigator 1 PFIZER INC. $11,059.20 07/03/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549213
Principal investigator 1 PFIZER INC. $10.82 06/29/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546395
Principal investigator 1 PFIZER INC. $46,499.84 06/26/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832543257
Principal investigator 1 PFIZER INC. $21,370.66 06/26/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548099
Principal investigator 1 PFIZER INC. $37,338.93 06/26/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549877
Principal investigator 1 SANOFI PASTEUR INC. $7,946.00 06/25/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366477
Principal investigator 1 PFIZER INC. $1,417.20 06/23/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542005
Principal investigator 1 PFIZER INC. $802.49 06/23/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544743
Principal investigator 1 PFIZER INC. $44,125.07 06/22/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544249
Principal investigator 1 PFIZER INC. $44,052.48 06/22/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832546217
Principal investigator 1 PFIZER INC. $13,344.26 06/12/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544147
Principal investigator 1 PFIZER INC. $51,895.18 06/09/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548719
Principal investigator 1 PFIZER INC. $6,357.26 06/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548417
Principal investigator 1 PFIZER INC. $725.00 06/05/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832546553
Principal investigator 1 SANOFI PASTEUR INC. $4,978.00 06/04/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366485
Principal investigator 1 PFIZER INC. $68,221.80 05/29/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832548599
Principal investigator 1 PFIZER INC. $2,330.10 05/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547007
Principal investigator 1 PFIZER INC. $1,417.20 05/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548703
Principal investigator 1 PFIZER INC. $802.49 05/25/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547843
Principal investigator 1 PFIZER INC. $1,418.75 05/22/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832543902
Principal investigator 1 PFIZER INC. $29,412.58 05/22/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549093
Principal investigator 1 PFIZER INC. $18,686.50 05/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544931
Principal investigator 1 PFIZER INC. $20,076.28 05/15/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543533
Principal investigator 1 PFIZER INC. $259.68 05/11/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547797
Principal investigator 1 PFIZER INC. $1,726.00 05/11/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549709
Principal investigator 1 PFIZER INC. $14,471.93 05/08/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549673
Principal investigator 1 PFIZER INC. $19,095.22 05/06/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542567
Principal investigator 1 PFIZER INC. $24,583.12 05/01/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547045
Principal investigator 1 PFIZER INC. $12,000.00 05/01/2021 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 832549801
Recipient PFIZER INC. $3,200.00 04/29/2021 Covered Recipient Physician COVID19 VACC CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832546951
Principal investigator 1 SANOFI PASTEUR INC. $13,976.00 04/28/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366469
Principal investigator 1 PFIZER INC. $863.00 04/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832545541
Principal investigator 1 PFIZER INC. $108.20 04/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546855
Principal investigator 1 PFIZER INC. $18,275.54 04/24/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547083
Principal investigator 1 PFIZER INC. $2,081.25 04/22/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832544441
Principal investigator 1 PFIZER INC. $13,780.76 04/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549419
Principal investigator 1 PFIZER INC. $28,711.10 04/17/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544939
Principal investigator 1 PFIZER INC. $108.20 04/16/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832541057
Principal investigator 1 PFIZER INC. $43.28 04/13/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542731
Principal investigator 1 PFIZER INC. $345.20 04/13/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546895
Principal investigator 1 PFIZER INC. $1,417.20 04/12/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832543659
Principal investigator 1 PFIZER INC. $802.49 04/12/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549083
Principal investigator 1 PFIZER INC. $26,844.61 04/10/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549447
Principal investigator 1 PFIZER INC. $4,075.00 04/09/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832545211
Principal investigator 1 PFIZER INC. $7,713.86 04/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546227
Principal investigator 1 PFIZER INC. $345.20 04/05/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548911
Principal investigator 1 PFIZER INC. $43.28 04/05/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549371
Principal investigator 1 PFIZER INC. $34,901.20 04/03/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832545635
Principal investigator 1 PFIZER INC. $75.74 03/31/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547995
Principal investigator 1 PFIZER INC. $604.10 03/31/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548051
Principal investigator 1 PFIZER INC. $44,002.56 03/27/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832545857
Principal investigator 1 PFIZER INC. $9,575.00 03/24/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832548031
Principal investigator 1 PFIZER INC. $345.20 03/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546117
Principal investigator 1 PFIZER INC. $43.28 03/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548279
Principal investigator 1 PFIZER INC. $108.20 03/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548353
Principal investigator 1 PFIZER INC. $863.00 03/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549389
Principal investigator 1 PFIZER INC. $696.28 03/22/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832549483
Principal investigator 1 PFIZER INC. $34,958.54 03/20/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832545237
Principal investigator 1 PFIZER INC. $61,872.36 03/20/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549073
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 03/19/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine MCV4 No dispute reported 06/30/2026 838366437
Principal investigator 1 SANOFI PASTEUR INC. $1,100.00 03/19/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine MCV4 No dispute reported 06/30/2026 838366443
Principal investigator 1 SANOFI PASTEUR INC. $2,681.00 03/19/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366461
Principal investigator 1 PFIZER INC. $696.28 03/15/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832547597
Principal investigator 1 PFIZER INC. $61,140.71 03/13/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544641
Principal investigator 1 PFIZER INC. $86.56 03/10/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549427
Principal investigator 1 PFIZER INC. $690.40 03/10/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549811
Principal investigator 1 PFIZER INC. $4,105.00 03/06/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832549821
Principal investigator 1 PFIZER INC. $72,607.44 03/06/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832549860
Principal investigator 1 SANOFI PASTEUR INC. $4,394.00 03/05/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366453
Recipient PFIZER INC. $3,200.00 03/04/2021 Covered Recipient Physician PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832506073
Principal investigator 1 PFIZER INC. $5,059.64 03/04/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832544117
Principal investigator 1 PFIZER INC. $179,790.08 02/27/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544177
Principal investigator 1 PFIZER INC. $75.74 02/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832534805
Principal investigator 1 PFIZER INC. $604.10 02/26/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547369
Principal investigator 1 PFIZER INC. $1,450.00 02/24/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832545061
Principal investigator 1 PFIZER INC. $16,212.86 02/23/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547273
Principal investigator 1 PFIZER INC. $28,588.24 02/20/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832546515
Principal investigator 1 PFIZER INC. $949.30 02/15/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832541903
Principal investigator 1 PFIZER INC. $119.02 02/15/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832545273
Principal investigator 1 PFIZER INC. $51,960.81 02/13/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547111
Principal investigator 1 PFIZER INC. $37,862.42 02/06/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832545793
Principal investigator 1 PFIZER INC. $4,187.50 02/05/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832543153
Principal investigator 1 PFIZER INC. $31,377.10 02/04/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546979
Principal investigator 1 PFIZER INC. $949.30 02/03/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546451
Principal investigator 1 PFIZER INC. $119.02 02/03/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548119
Principal investigator 1 PFIZER INC. $35,183.37 01/30/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832542539
Principal investigator 1 PFIZER INC. $99,687.28 01/23/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832543827
Principal investigator 1 SANOFI PASTEUR INC. $7,472.00 01/19/2021 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838366429
Principal investigator 1 PFIZER INC. $92,321.65 01/16/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832547399
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,017.80 01/15/2021 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826489475
Principal investigator 1 PFIZER INC. $11,173.90 01/15/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548997
Principal investigator 1 PFIZER INC. $86.56 01/13/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542715
Principal investigator 1 PFIZER INC. $690.40 01/13/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832549867
Principal investigator 1 PFIZER INC. $3,653.75 01/12/2021 Non-covered Recipient Entity
Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 832543297
Principal investigator 1 PFIZER INC. $54.10 01/11/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832542015
Principal investigator 1 PFIZER INC. $431.50 01/11/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832543731
Principal investigator 1 PFIZER INC. $142,665.16 01/08/2021 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832544279
Principal investigator 1 PFIZER INC. $4,407.92 01/08/2021 Non-covered Recipient Entity
Dr Shelly David Senders Inc DBA Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832546149
Principal investigator 1 PFIZER INC. $64.92 01/04/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832547416
Principal investigator 1 PFIZER INC. $517.80 01/04/2021 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832548749